

# Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics

Adam de Havenon, MD, Jennifer J. Majersik, MD, MS, David L. Tirschwell, MD, MSc, J. Scott McNally, MD, PhD, Gregory Stoddard, MPH, MBA, and Natalia S. Rost, MD, MPH

*Neurology*® 2019;92:e1168-e1175. doi:10.1212/WNL.0000000000007093

## Correspondence

Dr. de Havenon  
adam.dehavenon@  
hsc.utah.edu

## Abstract

### Objective

To determine whether higher blood pressure mean (BPM) or hemoglobin A1c is associated with progression of white matter hyperintensity (WMH) on MRI in patients with type 2 diabetes, and whether intensive blood pressure or glycemic control can reduce that progression.

### Methods

We performed a secondary analysis of the Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes (ACCORD MIND) research materials. The primary outcome is change in WMH volume ( $\Delta$ WMH) between a baseline and month-40 MRI, and the primary predictor is BPM and A1c between the MRIs. Additional analyses compared  $\Delta$ WMH in the intensive vs standard glycemic control randomization arms ( $n = 502$ ) and intensive vs standard blood pressure control randomization arms ( $n = 314$ ).

### Results

Higher systolic BPM, but not diastolic BPM or A1c, was associated with WMH progression. The  $\Delta$ WMH in tertiles of increasing systolic BPM ( $115 \pm 4$ ,  $127 \pm 3$ , and  $139 \pm 6$  mm Hg) was 0.7, 0.9, and 1.2  $\text{cm}^3$  ( $p < 0.001$ ).  $\Delta$ WMH was lower in the intensive vs standard blood pressure control randomization arm ( $\Delta$ WMH =  $0.67 \pm 0.95$  vs  $1.16 \pm 1.13$   $\text{cm}^3$ ,  $p < 0.001$ ), but there was no difference in the glycemic control arms ( $p = 0.917$ ).

### Conclusion


In ACCORD MIND, higher systolic blood pressure was associated with WMH progression. The intensive blood pressure control intervention reduced this progression. Comorbid diabetes and hypertension has synergistic deleterious properties that increase the risk of micro- and macrovascular complications. These results provide further support for an aggressive approach to blood pressure control in type 2 diabetics.

From the Department of Neurology (A.d.H., J.J.M., J.S.M., G.S.), University of Utah, Salt Lake City; Department of Neurology (D.L.T.), University of Washington, Seattle; Department of Neurology (N.S.R.), Harvard Medical School, Boston, MA.

Go to [Neurology.org/N](http://Neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

## Glossary

**ACCORD** = Action to Control Cardiovascular Risk in Diabetes; **BPM** = blood pressure mean; **BPV** = blood pressure variability; **CI** = confidence interval; **MIND** = Memory in Diabetes; **NHLBI** = National Heart, Lung, and Blood Institute; **PROGRESS** = Perindopril Protection Against Recurrent Stroke Study; **SPRINT** = Systolic Blood Pressure Intervention Trial; **WMH** = white matter hyperintensity.



NPub.org/900795

doi: 10.1212/WNL.0000000000007093

Copyright © 2019 American Academy of Neurology

Neurology®


White matter hyperintensity (WMH), also referred to as leukoaraiosis, is a neuroimaging finding detected on a fluid-attenuated inversion recovery MRI sequence and is most often attributed to cerebral small vessel disease (figure 1).<sup>1–5</sup> WMH burden can be measured with visual qualitative scales,<sup>6</sup> but the preferred methodology is algorithmic quantification of WMH volume.<sup>7</sup> The pathophysiology of WMH is not entirely understood, but the best clinical predictors of WMH burden are advanced age and hypertension.<sup>1,8–11</sup> A larger WMH burden is independently associated with impaired cognitive function, higher risk of both ischemic and hemorrhagic stroke, and worse clinical outcome after stroke.<sup>12–14</sup> Longitudinal observational studies show that uncontrolled hypertension and smoking are associated with the progression of WMH burden,<sup>15–17</sup> and effective control of hypertension can prevent WMH progression.<sup>18,19</sup>

The relationship between diabetes and WMH burden is controversial,<sup>20–23</sup> but the effect of intensive glycemic control on WMH progression is unknown. Furthermore, hypertension is common in diabetics, and when comorbid, diabetes and

hypertension have synergistic deleterious properties that increase the risk of both micro- and macrovascular complications.<sup>24–26</sup> Prior studies of WMH progression have not evaluated the effect of hypertension or glucose control in patients with diabetes mellitus. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was a double 2-by-2 factorial, parallel-group, randomized trial of patients aged 45 to 79 years with type 2 diabetes mellitus, elevated hemoglobin A1c concentration (>7.5%), and a high risk of cardiovascular disease events suggested by significant atherosclerosis, albuminuria, left ventricular hypertrophy, or at least 2 additional risk factors.<sup>27,28</sup> Patients were first randomized to intensive (target A1c <6.0%) or standard glycemic control (target A1c 7.0%–7.9%) and then, if they qualified, to multiple lipid management or blood pressure control strategies. Patients in the ACCORD Memory in Diabetes (MIND) ancillary trial had an MRI at baseline and again at 40 months from enrollment.<sup>29–31</sup>

The primary objectives of our study were to determine whether (1) patients in ACCORD MIND with higher systolic

**Figure 1** Axial fluid-attenuated inversion recovery images show characteristic scattered subcortical (A) and periventricular MRI hyperintensities (B) in a patient with a moderate burden of white matter hyperintensities



blood pressure mean (BPM) or A1c had more WMH progression and (2) patients randomized to the intensive blood pressure or glycemic control randomization arm had less WMH progression. As a secondary objective, we sought to determine whether higher visit-to-visit systolic blood pressure variability (BPV) could also predict WMH progression. In prior research, BPV has been associated with a higher risk of stroke, coronary artery disease, and chronic kidney disease.<sup>32–34</sup> However, the reported effects of BPV on WMH progression are controversial.<sup>35,36</sup> ACCORD MIND offers unique advantages to examine these hypotheses, including a large sample size, an extended follow-up period between study MRIs, and a standardized MRI protocol with semi-automated quantitative volumetric measurement of WMH.

## Methods

### Standard protocol approvals, registrations, and patient consents

This is a secondary analysis of the ACCORD research materials, a deidentified publicly available dataset. With a local


institutional review board waiver, we obtained the dataset from the National Heart, Lung, and Blood Institute (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center.

### Study population and outcomes

Our study has 2 cohorts (figure 2). The first cohort (n = 502) consists of patients enrolled in ACCORD MIND who had both study MRIs (baseline and month 40) and were randomized in the glycemic control trial. The second cohort (n = 314) is a subset of the first, limited to patients who were secondarily randomized to intensive blood pressure control (systolic target <120 mm Hg) or standard blood pressure control (systolic target <140 mm Hg). Patients were randomized to the glycemic or blood pressure control study arms prior to recruitment for the ACCORD MIND MRI substudy.

The primary outcome of our study is progression of WMH volume ( $\Delta$ WMH) between the ACCORD MIND baseline and month-40 MRI (figure 2). The MRI parameters and quality-control procedures used in ACCORD MIND have been previously described in detail.<sup>29,37</sup> The fluid-attenuated inversion recovery sequence parameters were as follows: repetition time 8,000 milliseconds (ms); inversion time 2,000 ms; echo time 100 ms; and voxel size 3.0 × 0.9 × 0.9 mm. Image quality was monitored according to the American College of Radiology’s MRI Quality Control Program ([acr.org/accreditation/mri.aspx](http://acr.org/accreditation/mri.aspx)). WMH volume was measured in cubic centimeters using a validated algorithmic approach.<sup>38,39</sup> We derived  $\Delta$ WMH by subtracting the WMH volume on the

**Figure 2** (A) Flowchart of the 2 study cohorts, and (B) study timeline showing both study MRIs (baseline and month 40) and blood pressure ascertainment period between the study MRIs



ACCORD = Action to Control Cardiovascular Risk in Diabetes; MIND = Memory in Diabetes.

baseline MRI from WMH volume on the month-40 MRI. A minority of patients had a negative value for  $\Delta$ WMH. This may have been related to differences in technique between MRI scans and/or regression of WMH burden, which has been previously described.<sup>40–42</sup>

### Statistical methods

To reduce confounding from the initial blood pressure reduction in the trial, only blood pressures collected between the study visit 3 months after randomization and the month-40 visit were used for calculations. BPM was calculated as the mean of all available systolic and diastolic blood pressure readings. BPV was evaluated with standard deviation, coefficient of variation, and average real variability, which we chose based on prior literature advocating multiple approaches for BPV evaluation.<sup>43</sup> The formulas for BPV calculation are:

$$SD = \sqrt{\left(\frac{1}{n-1}\right) \sum_{(i=1)}^{(n)} (BP_i - BP_{\text{mean}})^2}; CV = \left(\frac{SD}{BP_{\text{mean}}}\right) * 100; \text{ and } ARV = \left(\frac{1}{n-1}\right) \sum_{(i=1)}^{(n-1)} |BP_{i+1} - BP_i|.$$

Likewise, A1c values were included from the study visit 3 months after randomization to the month-40 visit to calculate the mean A1c.

For cohort 1, we investigated the clinical predictors of baseline WMH volume at trial enrollment by fitting unadjusted linear regression to baseline WMH volume in cubic centimeters. We evaluated the relationship between the predictors (BPM, randomization arms, and BPV) and  $\Delta$ WMH using linear regression models. We also examined tertiles of BPM and BPV in association with  $\Delta$ WMH and used analysis of variance to test for significance. For cohort 2, we compared characteristics between patients randomized to intensive or standard blood pressure control with the  $\chi^2$  test for categorical variables and Student *t* test for continuous variables. We fit multivariate linear regression models to  $\Delta$ WMH. Model 1 was adjusted for covariates chosen with backward selection set to a threshold of *p* value <0.1 and model 2 was adjusted for the same variables in model 1 as well as variables expected to influence  $\Delta$ WMH based on prior research. We conducted sensitivity analyses that

**Table 1** Patient demographics for cohort 1 and the 2 arms of cohort 2, which were tested for statistically significant differences

	Cohort 1 (n = 502)	Cohort 2, intensive BP arm (n = 153)	Cohort 2, standard BP arm (n = 161)	<i>p</i> Value for difference in cohort-2 arms <sup>a</sup>
Age, y, mean ± SD	62.7 ± 5.7	62.1 ± 4.8	62.6 ± 5.7	0.363
Female, n, %	232, 46.2	88, 57.5	79, 49.1	0.134
Caucasian, n, %	341, 67.9	107, 69.9	102, 63.4	0.217
Black, n, %	89, 17.7	29, 19.0	36, 22.4	0.457
Hypertension, n, %	474, 94.4	150, 98.0	155, 96.3	0.349
Hyperlipidemia, n, %	412, 82.1	133, 86.9	130, 80.8	0.138
Current smoking, n, %	50, 10.0	17, 11.1	19, 11.8	0.848
History of cardiovascular disease, n, %	127, 25.3	36, 23.5	46, 28.6	0.309
History of myocardial infarction, n, %	50, 10.0	11, 7.2	20, 12.4	0.120
History of stroke, n, %	16, 3.2	7, 4.6	5, 3.1	0.497
Hemoglobin A1c, %, mean ± SD	8.1 ± 0.9	8.2 ± 0.9	8.2 ± 1.0	0.948
Serum creatinine, mg/dL, mean ± SD	0.9 ± 0.2	0.9 ± 0.2	0.9 ± 0.2	0.511
LDL cholesterol, mg/dL, mean ± SD	101 ± 32	111 ± 37	101 ± 28	0.005
HDL cholesterol, mg/dL, mean ± SD	44 ± 12	48 ± 13	46 ± 13	0.110
Triglycerides, mg/dL, mean ± SD	192 ± 133	186 ± 123	198 ± 165	0.465
Intensive glycemic arm, n, %	229, 45.6	62, 40.5	80, 49.7	0.103
Baseline WMH volume, cm <sup>3</sup> , mean ± SD	1.76 ± 2.50	2.04 ± 2.85	1.80 ± 2.22	0.409
Final WMH volume, cm <sup>3</sup> , mean ± SD	2.68 ± 2.95	2.97 ± 2.77	2.71 ± 3.06	0.429
Change in WMH volume, cm <sup>3</sup> , mean ± SD	0.93 ± 1.20	0.67 ± 0.95	1.16 ± 1.13	<0.001

Abbreviations: BP = blood pressure; HDL = high-density lipoprotein; LDL = low-density lipoprotein; WMH = white matter hyperintensity.  
<sup>a</sup> Statistical significance tested with the  $\chi^2$  test for categorical variables and Student *t* test for continuous variables.

(1) adjusted  $\Delta$ WMH for the inpatient total brain volume, (2) excluded the outliers of  $\Delta$ WMH data (top and bottom 10%), or (3) was restricted to patients with a baseline WMH volume of  $\geq 1 \text{ cm}^3$ . Stata 15.1 (StataCorp LLC, College Station, TX) was used for all analyses with statistical significance defined as a 2-sided  $p$  value  $< 0.05$ .

### Data availability

The data in this study are publically available at [biolincc.nhlbi.nih.gov/studies/accord/?q=accord](https://biolincc.nhlbi.nih.gov/studies/accord/?q=accord).

## Results

The demographics of the 2 cohorts are shown in table 1. The number of blood pressure readings per patient (mean  $\pm$  SD) was  $13 \pm 5$  in cohort 1 and  $14 \pm 5$  in cohort 2. The absolute values of BPM and BPV for both cohorts are shown in table 2. For cohort 1 ( $n = 502$ ), the predictors of baseline WMH volume were patient age, history of hypertension, history of cardiovascular disease, stroke, or myocardial infarction, and serum creatinine level (table 3). Between the baseline and 40-month MRI, 420/502 (84%) had WMH progression, 61/502 (12%) had stable WMH, and 21/502 (4%) had WMH regression. The mean A1c during ACCORD was not

**Table 2** Factors associated with baseline WMH burden in cohort 1 ( $n = 502$ ), determined by linear regression fit to the outcome of baseline WMH volume in cubic centimeters

	$\beta$ Coefficient	95% CI	$p$ Value
Age, y	0.151	0.115, 0.188	$< 0.001$
Female	-0.326	-0.765, 0.113	0.145
Caucasian	0.443	-0.249, 0.912	0.063
Black	-0.304	-0.878, 0.270	0.298
Hypertension	0.954	0.002, 0.191	0.049
Hyperlipidemia	0.022	-0.550, 0.594	0.940
Current smoking	0.379	-0.352, 0.111	0.309
History of cardiovascular disease	0.879	0.380, 0.138	0.001
History of myocardial infarction	0.293	-0.439, 0.102	0.433
History of stroke	0.228	0.105, 0.351	$< 0.001$
Hemoglobin A1c	-0.723	-0.307, 0.162	0.545
Serum creatinine	1.51	0.438, 2.58	0.006
LDL cholesterol	0.005	-0.002, 0.012	0.126
HDL cholesterol	0.012	-0.006, 0.030	0.190
Triglycerides	-0.012	-0.003, 0.000	0.130

Abbreviations: CI = confidence interval; HDL = high-density lipoprotein; LDL = low-density lipoprotein; WMH = white matter hyperintensity.

**Table 3** BPM and BPV in both study cohorts for systolic and diastolic blood pressure

	Cohort 1 ( $n = 502$ )	Cohort 2, intensive BP arm ( $n = 153$ )	Cohort 2, standard BP arm ( $n = 161$ )
Systolic mean	$126.4 \pm 11.3$	$118.6 \pm 7.8$	$133.5 \pm 7.9$
Diastolic mean	$69.0 \pm 7.8$	$65.2 \pm 7.2$	$71.8 \pm 7.0$
Systolic SD	$11.2 \pm 4.2$	$10.5 \pm 3.4$	$11.5 \pm 4.3$
Diastolic SD	$6.4 \pm 2.0$	$6.2 \pm 1.5$	$6.3 \pm 2.2$
Systolic CV	$8.8 \pm 2.9$	$8.9 \pm 2.7$	$8.6 \pm 3.1$
Diastolic CV	$9.3 \pm 2.9$	$9.6 \pm 2.3$	$8.8 \pm 2.9$
Systolic ARV	$12.8 \pm 5.4$	$11.7 \pm 4.1$	$13.3 \pm 6.0$
Diastolic ARV	$7.3 \pm 2.5$	$6.9 \pm 1.8$	$7.2 \pm 2.7$

Abbreviations: ARV = average real variability (mm Hg); BP = blood pressure; BPM = blood pressure mean; BPV = blood pressure variability; CV = coefficient of variation (%); SD = standard deviation (mm Hg).

associated with  $\Delta$ WMH (coefficient =  $-0.04$ , 95% confidence interval [CI] =  $-0.15, 0.08$ ,  $p = 0.540$ ). Randomization to intensive or standard glycemic control was not associated with  $\Delta$ WMH (standard glycemic control arm  $\Delta$ WMH =  $0.92 \pm 1.31 \text{ cm}^3$ , intensive glycemic control  $\Delta$ WMH =  $0.93 \pm 1.06 \text{ cm}^3$ ,  $p = 0.917$ ), and the interaction term between the blood pressure and glucose control randomization arms was not significant ( $p = 0.523$ ). Systolic BPM, but not diastolic BPM or any measures of BPV, was associated with  $\Delta$ WMH (table 4). The mean  $\Delta$ WMH in the tertiles of increasing systolic BPM was 0.7, 0.9, and  $1.2 \text{ cm}^3$  ( $p_{\text{trend}} < 0.001$ ) for corresponding systolic BPMs of  $115 \pm 4$ ,  $127 \pm 3$ , and  $139 \pm 6 \text{ mm Hg}$ .

In cohort 2 ( $n = 314$ ), 153/314 (49%) were randomized to the intensive blood pressure control arm. There was a 15 mm Hg difference in the systolic BPM between the 2 arms (intensive arm BPM =  $118.6 \pm 7.8 \text{ mm Hg}$ , standard arm BPM =  $133.5 \pm 7.9 \text{ mm Hg}$ ,  $p < 0.001$ ).  $\Delta$ WMH was lower in the intensive blood pressure control arm (intensive arm  $\Delta$ WMH =  $0.67 \pm 0.95 \text{ cm}^3$ , standard arm  $\Delta$ WMH =  $1.16 \pm 1.13 \text{ cm}^3$ ,  $p < 0.001$ ). There was a strong relationship between  $\Delta$ WMH and the blood pressure randomization arm (coefficient =  $-0.50$ , 95% CI =  $-0.73, -0.27$ ,  $p < 0.001$ ), which remained significant after adjusting for patient age, sex, baseline WMH volume, history of stroke, serum creatinine, and the glycemic control randomization arm (coefficient =  $-0.46$ , 95% CI =  $-0.69, -0.23$ ,  $p < 0.001$ ).

## Discussion

Higher mean systolic blood pressure is associated with progression of WMH over 40 months in patients with type 2 diabetes and a high risk of cardiovascular events. Furthermore, patients who were randomized to the intensive blood pressure

**Table 4** Association of 10 mm Hg shift in BPM and BPV with  $\Delta$ WMH in multivariate linear regression models of cohort 1 (n = 502)

	Model 1		Model 2	
	$\beta$ Coefficient (95% CI)	p Value	$\beta$ Coefficient (95% CI)	p Value
Systolic mean	0.116 (0.026, 0.207)	0.012	0.125 (0.032, 0.217)	0.008
Systolic SD	0.146 (−0.098, 0.391)	0.241	0.167 (−0.082, 0.416)	0.188
Systolic CV	0.097 (−0.240, 0.433)	0.572	0.120 (−0.221, 0.460)	0.491
Systolic ARV	0.120 (−0.067, 0.307)	0.209	0.131 (−0.059, 0.321)	0.175
Diastolic mean	0.113 (−0.025, 0.251)	0.108	0.120 (−0.020, 0.260)	0.093
Diastolic SD	−0.017 (−0.589, 0.427)	0.755	−0.047 (−0.564, 0.469)	0.857
Diastolic CV	−0.156 (−0.514, 0.202)	0.393	−0.139 (−0.502, 0.225)	0.454
Diastolic ARV	0.008 (−0.398, 0.414)	0.970	0.026 (−0.385, 0.437)	0.902

Abbreviations: ARV = average real variability; BPM = blood pressure mean; BPV = blood pressure variability; CI = confidence interval; CV = coefficient of variation; SD = standard deviation; WMH = white matter hyperintensity.

Model 1: adjusted for patient age, sex, baseline volume of WMH, history of stroke, and history of myocardial infarction. Model 2: adjusted for patient age, sex, baseline volume of WMH, history of stroke, history of myocardial infarction, history of hypertension, mean hemoglobin A1c, current tobacco smoking, white race, and low-density lipoprotein cholesterol.

control arm had WMH progression that was nearly half that of patients randomized to standard blood pressure control (0.67 vs 1.16 cm<sup>3</sup>). We did not find that glycemic control was associated with WMH progression or that it interacted with blood pressure control. Similar to prior research, the baseline WMH burden was associated with advancing patient age and hypertension, but also a history of cardiovascular disease or stroke and the level of serum creatinine.

These results are consistent with the Three-City (3C)–Dijon Magnetic Resonance Imaging Study and the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy, which found that with more successful blood pressure control, patients had reduced progression of WMH over a 36-month period.<sup>18,19</sup> A substudy of the PRoFESS (Prevention Regimen for Effectively Avoiding Second Strokes) trial failed to reach this conclusion but had notable weaknesses, including a shorter follow-up period and the study's dichotomization of patients into telmisartan vs placebo cohorts.<sup>44</sup> This resulted in a negligible difference (3 mm Hg) in systolic blood pressure between the cohorts, compared to 11 mm Hg for the PROGRESS substudy and 15 mm Hg in our analysis of ACCORD MIND.

The effect size of intensive blood pressure control on WMH progression in this cohort is similar to Systolic Blood Pressure Intervention Trial Memory and Cognition in Decreased Hypertension (SPRINT-MIND), which was recently presented, but has not yet been published.<sup>45</sup> In the SPRINT-MIND intensive blood pressure control arm, WMH volume increased by 0.28 vs 0.92 cm<sup>3</sup> in the standard blood pressure control arm ( $p = 0.004$ ). Several differences should be highlighted between our analysis and the SPRINT-MIND data.

The first is that the follow-up MRIs were performed at 48 months, instead of the 40-month interval in ACCORD, and despite longer follow-up, the WMH progression in SPRINT-MIND was less than in ACCORD patients. This supports the proposition that hypertension and diabetes have a synergistic negative effect on WMH progression. Although our data did not find that ACCORD's intensive glucose control intervention reduced WMH progression, we do find that the intensive blood pressure control attenuates progression. Thus, our analysis supports the benefit of blood pressure reduction in the higher risk group of diabetic patients.

Unlike several prior studies, we did not find an association between visit-to-visit BPV and WMH progression. Two of the studies that reported this association relied on blood pressure readings from only 3 study visits,<sup>46,47</sup> while patients in our analysis had a minimum of 6 visits and a mean of 13 for cohort 1 and 14 for cohort 2. The statistical measurement of variability improves with the number of available data, and these prior studies may have found an erroneous association attributable to undersampling. Indeed, a study of 584 patients with prior stroke that had between 12 and 18 blood pressure measurements per patient failed to find a link between BPV and WMH progression.<sup>48</sup> Nonetheless, a prospective randomized trial is necessary to fully disprove the association.

This study has several strengths. The ACCORD and ACCORD MIND trials offer exceptionally high-quality data and a large sample size with a long period of follow-up between study MRIs. The standardized MRI protocol and semi-automated quantitative volumetric measurement of WMH, which is the preferred methodology, are unique advantages that have not been available to prior studies. The ability to focus specifically on patients with diabetes and a high risk of

cardiovascular events is novel and should help guide future studies focusing on delaying the progression of WMH in patients at the highest risk of progression. The sensitivity analyses did not change the conclusions of our study (data not shown), thus further reinforcing our findings. The weaknesses of our study include a potential selection bias because patients voluntarily agreed to participate in the ACCORD MIND MRI substudy, residual confounding in our multivariate regression models, a limited number of blood pressure readings to evaluate mean and variability, and blood pressure measurements from office visits only. Future studies should consider ambulatory blood pressure readings, which may be a more accurate predictor of WMH progression.<sup>49</sup> High-resolution volumetric MRI sequences could also be used to more precisely evaluate WMH volume progression, accurately determine localization, and define the relationship to changes in perivascular spaces and overall parenchymal volume.

Our finding that higher systolic blood pressure was associated with WMH progression in diabetics, and that progression was attenuated by an intensive blood pressure control intervention, provides further support for an aggressive approach to blood pressure control in type 2 diabetics.

### Author contributions

A.d.H and N.S.R. were responsible for study design, manuscript drafting, and manuscript editing. Ad.H. and G.S. were responsible for statistical analysis. D.L.T., J.J.M., and J.S.M. were responsible for manuscript drafting and editing.

### Acknowledgment

This article was prepared using ACCORD Research Materials obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of ACCORD or the NHLBI.

### Study funding

Research reported in this publication was supported by an American Heart Association Scientist Development Grant 17SDG33670114 (Dr. de Havenon). The content is solely the responsibility of the authors and does not represent the official views of the American Heart Association. Dr. Rost is in part supported by NIH-NINDS grants R01NS082285 and R01NS086905.

### Disclosure

The authors report no disclosures relevant to the manuscript. Go to [Neurology.org/N](http://Neurology.org/N) for full disclosures.

### Publication history

Received by *Neurology* April 24, 2018. Accepted in final form November 1, 2018.

### References

- Basile AM, Pantoni L, Pracucci G, et al. Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. *Cerebrovasc Dis* 2006;21:315–322.

- Schmidt R, Fazekas F, Kapeller P, Schmidt H, Hartung HP. MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. *Neurology* 1999;53:132–139.
- Liao D, Cooper L, Cai J, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control: the ARIC study. *Stroke* 1996;27:2262–2270.
- Wardlaw JM, Hernández MCV, Muñoz-Maniega S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. *J Am Heart Assoc* 2015;4:e001140.
- Etherton MR, Wu O, Rost NS. Recent advances in leukoaraiosis: white matter structural integrity and functional outcomes after acute ischemic stroke. *Curr Cardiol Rep* 2016;18:123.
- Fazekas F, Barkhof F, Wahlund LO, et al. CT and MRI rating of white matter lesions. *Cerebrovasc Dis* 2002;13(suppl 2):31–36.
- Rost NS, Sadaghiani S, Biffi A, et al. Setting a gold standard for quantification of leukoaraiosis burden in patients with ischemic stroke: the Atherosclerosis Risk in Communities Study. *J Neurosci Methods* 2014;221:196–201.
- Habes M, Erus G, Toledo JB, et al. White matter hyperintensities and imaging patterns of brain ageing in the general population. *Brain* 2016;139:1164–1179.
- de Leeuw FE, de Groot JC, Oudkerk M, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. *Brain J Neurol* 2002;125:765–772.
- de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. *J Neurol Neurosurg Psychiatry* 2001;70:9–14.
- Henskens LH, Kroon AA, van Oostenbrugge RJ, et al. Associations of ambulatory blood pressure levels with white matter hyperintensity volumes in hypertensive patients. *J Hypertens* 2009;27:1446–1452.
- Au R, Massaro JM, Wolf PA, et al. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. *Arch Neurol* 2006;63:246–250.
- Rost NS, Rahman RM, Biffi A, et al. White matter hyperintensity volume is increased in small vessel stroke subtypes. *Neurology* 2010;75:1670–1677.
- Kuller LH, Longstreth WT, Arnold AM, Bernick C, Bryan RN, Beauchamp NJ. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. *Stroke* 2004;35:1821–1825.
- Power MC, Deal JA, Sharrett AR, et al. Smoking and white matter hyperintensity progression: the ARIC-MRI Study. *Neurology* 2015;84:841–848.
- Gottesman RF, Coresh J, Catellier DJ, et al. Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk in Communities (ARIC) study. *Stroke* 2010;41:3–8.
- Longstreth WT, Arnold AM, Beauchamp NJ, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. *Stroke* 2005;36:56–61.
- Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) magnetic resonance imaging substudy. *Circulation* 2005;112:1644–1650.
- Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study. *Circulation* 2011;123:266–273.
- van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging in patients with diabetes: a systematic review. *Diabetes Care* 2006;29:2539–2548.
- Longstreth WT, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. *Stroke* 1996;27:1274–1282.
- Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. *Diabetes Care* 2013;36:4036–4042.
- Liao D, Cooper L, Cai J, et al. The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC Study. *Neuroepidemiology* 1997;16:149–162.
- Song Y, Liu X, Zhu X, et al. Increasing trend of diabetes combined with hypertension or hypercholesterolemia: NHANES data analysis 1999–2012. *Sci Rep* 2016;6:36093.
- Bell DS. Hypertension and diabetes: a toxic combination. *Endocr Pract* 2008;14:1031–1039.
- Giunti S, Cooper M. Management strategies for patients with hypertension and diabetes: why combination therapy is critical. *J Clin Hypertens* 2006;8:108–113.
- ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1575–1585.
- Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545–2559.
- Launer LJ, Miller ME, Williamson JD, et al. Effects of randomization to intensive glucose lowering on brain structure and function in type 2 diabetes (ACCORD MIND): a randomised open-label substudy. *Lancet Neurol* 2011;10:969–977.
- Murray AM, Hsu FC, Williamson JD, et al. ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial. *Diabetologia* 2017;60:69–80.
- Williamson JD, Launer LJ, Bryan RN, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. *JAMA Intern Med* 2014;174:324.

32. Mancia G. Visit-to-visit blood pressure variability. *Hypertension* 2016;68:32–33.
33. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. *Lancet* 2010; 375:895–905.
34. Muntner P, Whittle J, Lynch AJ, et al. Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure and mortality: a cohort study. *Ann Intern Med* 2015;163:329–338.
35. Nagai M, Kario K. Visit-to-visit blood pressure variability, silent cerebral injury, and risk of stroke. *Am J Hypertens* 2013;26:1369–1376.
36. Gunstad J, Cohen RA, Tate DF, et al. Blood pressure variability and white matter hyperintensities in older adults with cardiovascular disease. *Blood Press* 2005;14: 353–358.
37. Williamson JD, Miller ME, Bryan RN, et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. *Am J Cardiol* 2007;99:112i–122i.
38. Lao Z, Shen D, Liu D, et al. Computer-assisted segmentation of white matter lesions in 3D MR images using support vector machine. *Acad Radiol* 2008;15: 300–313.
39. Goldszal AF, Davatzikos C, Pham DL, Yan MX, Bryan RN, Resnick SM. An image-processing system for qualitative and quantitative volumetric analysis of brain images. *J Comput Assist Tomogr* 1998;22:827–837.
40. Adachi M, Sato T. Characterization of the growth of deep and subcortical white matter hyperintensity on MR imaging: a retrospective cohort study. *Magn Reson Med* 2017;16:238–244.
41. Wardlaw JM, Chappell FM, Valdés Hernández MC, et al. White matter hyperintensity reduction and outcomes after minor stroke. *Neurology* 2017;89:1003–1010.
42. Cho AH, Kim HR, Kim W, Yang DW. White matter hyperintensity in ischemic stroke patients: it may regress over time. *J Stroke* 2015;17:60–66.
43. Manning LS, Rothwell PM, Potter JF, Robinson TG. Prognostic significance of short-term blood pressure variability in acute stroke systematic review. *Stroke* 2015;46: 2482–2490.
44. Weber R, Weimar C, Blatchford J, et al. Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) MRI substudy. *Stroke* 2012;43:2336–2342.
45. National Institutes of Health. NIH-funded researchers present preliminary clinical trial results suggesting aggressive blood pressure control may lower risk of cognitive impairment [online]. 2018. Available at: [nih.gov/news-events/news-releases/nih-funded-researchers-present-preliminary-clinical-trial-results-suggesting-aggressive-blood-pressure-control-may-lower-risk-cognitive-impairment](http://nih.gov/news-events/news-releases/nih-funded-researchers-present-preliminary-clinical-trial-results-suggesting-aggressive-blood-pressure-control-may-lower-risk-cognitive-impairment). Accessed August 16, 2018.
46. Brickman AM, Reitz C, Luchsinger JA, et al. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. *Arch Neurol* 2010;67:564–569.
47. Havlik RJ, Foley DJ, Sayer B, Masaki K, White L, Launer LJ. Variability in midlife systolic blood pressure is related to late-life brain white matter lesions: the Honolulu-Asia Aging Study. *Stroke* 2002;33:26–30.
48. Liu W, Liu R, Sun W, et al. Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions. *Stroke* 2012;43: 2916–2922.
49. White WB, Wolfson L, Wakefield DB, et al. Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people. *Circulation* 2011;124:2312–2319.

# Neurology®

## Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics

Adam de Havenon, Jennifer J. Majersik, David L. Tirschwell, et al.  
*Neurology* 2019;92:e1168-e1175 Published Online before print February 8, 2019  
DOI 10.1212/WNL.0000000000007093

**This information is current as of February 8, 2019**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/92/11/e1168.full">http://n.neurology.org/content/92/11/e1168.full</a>
<b>References</b>	This article cites 48 articles, 20 of which you can access for free at: <a href="http://n.neurology.org/content/92/11/e1168.full#ref-list-1">http://n.neurology.org/content/92/11/e1168.full#ref-list-1</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All Cerebrovascular disease/Stroke</b> <a href="http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke">http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke</a> <b>Volumetric MRI</b> <a href="http://n.neurology.org/cgi/collection/volumetric_mri">http://n.neurology.org/cgi/collection/volumetric_mri</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

